Announcing Two New Published Studies Involving ReadiSorb Glutathione and RSV, COVID-19
Palo Alto, CA, May 2, 2024 - Your Energy Systems, LLC (ReadiSorb®), a leading provider of high-quality health supplements, proudly announces the publication of two groundbreaking studies on PubMed, showcasing the efficacy of ReadiSorb® Liposomal Glutathione (RLG) to restore glutathione, the lack of which plays a critical role in mediation, aggravation and replication of viral illnesses, particularly Respiratory Syncytial Virus (RSV) and the Spike protein of COVID-19.
The recently published studies shed light on the significant benefits of utilizing ReadiSorb® Liposomal Glutathione in boosting the immune system to combat viral infections. One study, focusing on the Spike protein of COVID-19 in cell culture of normal human immune cells, highlights the pivotal role of glutathione in preventing immunothrombosis related to the Spike protein, which facilitates the entry of the virus into cells. The findings underscore the potential of ReadiSorb® to restore glutathione, which restoration mitigates immunologic and thrombotic events associated with COVID-19.
Moreover, a separate study conducted on GSH-depleted mice further validates the efficacy of RLG in augmenting immune defense against Respiratory Syncytial Virus (RSV) infections. The study uses objective criteria to demonstrate RLG’s support of immune defenses against RSV in neonatal mice depleted of GSH by ethanol in utero, and highlights the potential of RLG to enhance immune response to viral infections resulting from glutathione deficiency of critical biochemical pathways in vulnerable populations.
"These groundbreaking studies underscore the significant impact of ReadiSorb® Liposomal Glutathione (RLG) to enhance intracellular glutathione to significantly reduce viral load in an animal model," stated Tim Guilford, MD, Science Officer at ReadiSorb®. "Many viral illnesses decrease the nutrient GSH to facilitate their replication. We are thrilled to see the growing body of evidence supporting the efficacy of RLG in enhancing immune responses and restoring glutathione, depletion of which can occur in some infections, including those caused by COVID-19 and RSV."
The studies are now available for reference:
- Evaluation of Glutathione in Spike Protein of SARS-CoV-2 Induced Immunothrombosis and Cytokine Dysregulation
- Liposomal Glutathione Augments Immune Defenses against Respiratory Syncytial Virus in Neonatal Mice Exposed in Utero to Ethanol
About ReadiSorb®
Established in 2004, ReadiSorb® has been a trusted provider of high-quality supplements, proudly manufactured in California. Renowned for pioneering the first liposomal glutathione with published research, ReadiSorb has since amassed a significant body of evidence supporting its products, with 14 studies, including 4 clinical trials, validating their efficacy and safety.
We encourage reading about the advantages of ReadiSorb® Glutathione, with comprehensive information available at www.readisorb.com/advantages. To discover more about ReadiSorb® and its range of health supplements, please visit www.readisorb.com. The full list of studies is available on www.liposomalglutathione.com.